BioSpace News Archive

NKGen Biotech today announced that a Phase I study of SNK01 monotherapy in refractory cancers has been accepted for presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting being held virtually November 10 – 13, 2021.

the Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced positive topline results from the EMERALD study.

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will report operating and financial results for the third quarter ended September 30, 2021 after the market close on Tuesday, November 2, 2021.

Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced that it has completed the previously announced acquisition of Agena Biosciences, Inc.

RedHill Biopharma Ltd. will present a corporate overview at the BIO-Europe Digital Conference, taking place October 25-28, 2021.

ViaCyte, Inc. will present at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 11:30 a.m. ET

Stealth BioTherapeutics Corp today announced that it received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding Stealth’s New Drug Application (NDA) for elamipretide, a mitochondria-targeted therapy for the treatment of Barth syndrome.

Alopexx, Inc. a clinical stage biotechnology company focused on developing novel, broad-spectrum immune-mediated therapeutics for the prevention and treatment of bacterial, fungal and parasitic infections, announced that Thomas T. Thomas has joined the Company as chief financial officer.

Albert Einstein College of Medicine has received a five-year, $4 million grant from the National Institutes of Health to support the New York Regional Center for Diabetes Translation Research.

Viome Life Sciences, today announced the expansion of its two-year partnership with GSK, a science-led global healthcare company, to expand clinical research activities1 and potential development of new therapeutic interventions within the fields of chronic diseases including autoimmune diseases and cancers.